Teachers Advisors LLC grew its position in Puma Biotechnology Inc (NASDAQ:PBYI) by 25.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 210,470 shares of the biopharmaceutical company’s stock after buying an additional 42,091 shares during the period. Teachers Advisors LLC owned approximately 0.55% of Puma Biotechnology worth $9,650,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Resources Management Corp CT ADV bought a new position in Puma Biotechnology in the 3rd quarter valued at about $101,000. Macquarie Group Ltd. raised its holdings in Puma Biotechnology by 37.2% in the 3rd quarter. Macquarie Group Ltd. now owns 648,463 shares of the biopharmaceutical company’s stock valued at $29,732,000 after acquiring an additional 175,699 shares during the period. MetLife Investment Advisors LLC grew its position in shares of Puma Biotechnology by 53.0% during the 3rd quarter. MetLife Investment Advisors LLC now owns 21,107 shares of the biopharmaceutical company’s stock worth $968,000 after purchasing an additional 7,316 shares in the last quarter. Sio Capital Management LLC acquired a new position in shares of Puma Biotechnology during the 3rd quarter worth approximately $1,505,000. Finally, Verition Fund Management LLC acquired a new position in shares of Puma Biotechnology during the 3rd quarter worth approximately $527,000. 92.10% of the stock is owned by institutional investors.
In related news, insider Charles R. Eyler sold 1,239 shares of the stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $22.77, for a total transaction of $28,212.03. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Alan H. Auerbach sold 8,825 shares of the stock in a transaction that occurred on Tuesday, January 22nd. The stock was sold at an average price of $24.74, for a total transaction of $218,330.50. Following the sale, the insider now owns 4,165,812 shares in the company, valued at approximately $103,062,188.88. The disclosure for this sale can be found here. Insiders have sold a total of 14,833 shares of company stock worth $347,578 in the last quarter. 21.50% of the stock is currently owned by company insiders.
Shares of NASDAQ PBYI traded up $0.07 during trading hours on Monday, hitting $26.39. 7,426 shares of the stock were exchanged, compared to its average volume of 769,348. The company has a current ratio of 3.01, a quick ratio of 2.96 and a debt-to-equity ratio of 2.64. The firm has a market capitalization of $1.00 billion, a price-to-earnings ratio of -3.34 and a beta of 0.61. Puma Biotechnology Inc has a 1-year low of $17.60 and a 1-year high of $83.15.
A number of research analysts have issued reports on PBYI shares. Cantor Fitzgerald increased their target price on shares of Puma Biotechnology to $55.00 in a research report on Tuesday, December 18th. Cowen set a $68.00 target price on shares of Puma Biotechnology and gave the stock a “hold” rating in a research report on Friday, November 2nd. Zacks Investment Research lowered shares of Puma Biotechnology from a “buy” rating to a “hold” rating in a research report on Wednesday, November 14th. Leerink Swann started coverage on shares of Puma Biotechnology in a research report on Thursday, January 17th. They set a “market perform” rating and a $21.00 target price on the stock. Finally, Guggenheim lowered shares of Puma Biotechnology from a “buy” rating to a “neutral” rating in a research report on Thursday, January 3rd. Six analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company’s stock. Puma Biotechnology currently has a consensus rating of “Hold” and an average target price of $58.73.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2019/02/11/puma-biotechnology-inc-pbyi-shares-bought-by-teachers-advisors-llc.html.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).
Recommended Story: What is a bull market?
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.